Annual Report 2022/2023 Presentation

A recurring issue this year has been that of insider buying and financing. To my knowledge, there have been no insider purchases in the last year and this has definitely had a negative impact on investors. You've mentioned the reason for MAR before, but it's been almost a year and it's hard to see that there hasn't been a gap for purchases.

You have managed to get FDA approvals all around, wouldn't it have been an idea to really invest in markets you already have and be able to get sales going there properly?

The turnover in the share is extremely low, which affects both old and possible new investors, how is it that you do not manage to create interest in the company?

The absolute most important thing for both you and us investors is what financing looks like in the future, I can't see how it can be so difficult to get financing if a sales agreement is in place? Over the years, you have promised not to dilute the share, is this something you regret today and if so, have you been able to obtain financing via the stock exchange? And how do you think you would attract investors on the stock exchange to want to put in money when nothing has gone as promised since the last financing?

What happened to the payment in january?

Just thinking about yesterday's memo regarding sales to Jordan, you had lots of similar agreements in 2022-2023 that you really didn't manage to fulfil in terms of sales and income, what will be the difference this time?

And in addition, once you have worked out such a nice agreement that should be worth a lot of money for the company, so at the news release yesterday 4000 shares were traded, why do you think that is?

That said, it would be nice to have a memo with actual money coming into the company.

In the last webinar you promised to be more restrictive with your forecasts going forward, and the most important forecast since then was the payment from China which was projected for January, how do you see that?

I don't know if it's rude to point out, but if you have the products, how come you don't try to sell the company and take it off the stock market. I mean, Rong-Shi's possible financing is on par with the entire market capitalisation right now? The first FDA approval from there was planned for August, right?

You have often emphasised that you are the first mover in the medical CBD, given the countless delays, is there a chance that you will miss the opportunity and competitors will overtake you?

Can you provide more information into the funding situation. What kind of funding opportunities are you pursuing and how will you make sure to obtain the funding you need in the nearest future. It seems like at the moment you are just filling holes with small short term funding and loans but not really capturing the funding to focus on the future and growing the company - so what is the plan?

Of your order pipeline can you provide some more insights. Of the pipeline how much is orders to first time buyers and how much of it is to existing customers ordering again?